Vapotherm, Inc. (VAPO) stock declined in the current market after announcing preliminary results for 2022. VAPO stock is valued at $9.01, gaining more than 30.36% from the previous close. VAPO stock closed at $12.91 at the end of the last trading session with a trading volume of 136.43K shares.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Medical Devices Industry Overview
After the Covid-19 pandemic, there has been a significant rise in the demand for medical devices. Most of the biotech and pharmaceutical companies were spending a lot of money on R&D to find treatments for coronavirus disease. Due to the pandemic, the supply chain was disrupted, and there was a global shortage in the supply of medical devices. So the solution was to domestically produce medical devices, which every country did and tried to control the situation.
As per the statistics, the medical devices industry was valued at around $532.62 billion in 2021. And according to the historical data, it is expected that the global medical devices industry will grow at a compound annual growth rate of 5.5% to reach $734.39 billion in 2027. The significant impact on the rise in this industry was the Covid-19 pandemic.
VAPO: Q1 Preliminary Results
Vapotherm, Inc. (VAPO) announced in a press release on April 6, 2022, that they are expecting revenue for the first quarter of 2022 to be between $20.5 million to $21.5 million. In 2021, first-quarter revenue was $32.3 million.
After the trading session closes, the company plans to release its first-quarter 2022 results on Wednesday, May 4, 2022. The management will hold a conference call and host the call at 4:30 p.m. ET.
VAPO: Fiscal 2022 Outlook
This year’s revenue, gross margin, operating expenditure, and adjusted EBITDA estimates have been withdrawn. It was assumed that in 2022, there would be two COVID-19 spikes, each generating income equal to half of the previous surges. COVID-19’s virulence seems to be decreasing, leading to fewer acute respiratory interventions, and seasonal hospitalization trends associated with flu and RSV have decreased in the first quarter; therefore, the company has decided to retract its guidance.
The company has taken back its guidance for fiscal 2022 because of the wrong estimation of coronavirus waves. It could be used as an opportunity to perform well in the market and increase its revenue.